Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Key Highlights
- ➤Merger completed, creating Supernus, Inc. as a diversified CNS biopharmaceutical company
- ➤11-product portfolio includes five core growth drivers: SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE
- ➤Indivior stockholders receive $1.0 billion special cash dividend, partly financed by $650 million term loan
- ➤Former Indivior stockholders own approximately 56.5% of combined company; Supernus stockholders own 43.5%
- ➤Combined company begins Nasdaq trading under SUPN on November 3, 2026
Expert Statements
Jack Khattar, President and CEO of Supernus, Inc.
“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions. As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”
Tony Kingsley, Chair of the Board of Directors of Supernus, Inc.
“This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”
* Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline * Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities * Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026 ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)(1) today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.
Get started
Create a free account to read the full story.